OHM Laboratories Inc

OHM Laboratories Inc is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. Established in 1981 and headquartered in New Brunswick, New Jersey, OHM Laboratories has been a significant player in the U.S. pharmaceutical distribution network. In 1995, the company was acquired by Ranbaxy Laboratories, which was subsequently acquired by Sun Pharmaceutical Industries in 2014, integrating OHM Laboratories into Sun Pharma's global operations. (cdek.pharmacy.purdue.edu)

As a subsidiary of Sun Pharma, OHM Laboratories Inc plays a pivotal role in sourcing and importing a diverse range of pharmaceutical products, ensuring the availability of essential medications in the U.S. market. The company's operations are integral to Sun Pharma's distribution strategy, facilitating the delivery of high-quality, affordable medications to healthcare providers and patients across the United States.

OHM Laboratories Inc operates a comprehensive distribution network within the United States, with facilities located in New Brunswick, New Jersey, and Princeton, New Jersey. These strategically positioned facilities enable efficient logistics and supply chain management, ensuring timely delivery of pharmaceutical products to various regions. The company's distribution capabilities are further enhanced by its integration with Sun Pharmaceutical Industries, leveraging Sun Pharma's extensive global logistics infrastructure to support its operations.

In the U.S. pharmaceutical supply chain, OHM Laboratories Inc functions primarily as a pharmaceutical importer and buyer, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. The company's role is crucial in ensuring the availability of a wide array of generic medications, contributing to the affordability and accessibility of healthcare in the United States. By importing these products, OHM Laboratories Inc supports the U.S. market with a steady supply of essential drugs, thereby enhancing the overall efficiency and resilience of the pharmaceutical supply chain.

OHM Laboratories Inc demonstrates a high degree of sourcing concentration, with a total import value of $9.5 million USD from India, comprising 208 shipments across seven products in three therapeutic categories. Notably, the company imports 95.8% of its products from a single supplier, SUN PHARMACEUTICAL INDUSTRIES LIMITED, which accounts for $13.0 million USD in imports over 425 shipments. (cdek.pharmacy.purdue.edu)

This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and potentially leverage favorable terms with a primary supplier. However, such concentration also poses risks, including vulnerability to supply disruptions or changes in supplier dynamics. The stability of this relationship is critical, and the absence of alternative suppliers may impact OHM Laboratories Inc's ability to mitigate potential supply chain challenges.

The resilience of OHM Laboratories Inc's Indian supply chain is closely tied to its exclusive partnership with SUN PHARMACEUTICAL INDUSTRIES LIMITED. The lack of backup suppliers for the imported formulations suggests a potential vulnerability in the event of supply disruptions. Additionally, the company's reliance on a single supplier may limit its ability to diversify its product offerings or respond to market changes effectively.

Shipping route exposure is also a consideration, as reliance on specific logistics channels can be susceptible to geopolitical or logistical challenges. Regulatory compliance of SUN PHARMACEUTICAL INDUSTRIES LIMITED is paramount, and any lapses could directly affect OHM Laboratories Inc's operations. Ensuring that SUN PHARMACEUTICAL INDUSTRIES LIMITED adheres to all relevant regulatory standards is essential for maintaining the integrity and reliability of the supply chain.

The sourcing pattern of OHM Laboratories Inc, characterized by a high concentration with a single supplier, positions the company to benefit from streamlined operations and potentially favorable terms. However, this strategy also exposes the company to risks associated with supply chain disruptions, regulatory changes, or shifts in supplier performance. For Indian exporters seeking to become alternative suppliers, understanding the dynamics of this relationship is crucial. Offering competitive pricing, ensuring consistent product quality, and demonstrating reliability in meeting regulatory standards could present opportunities to diversify OHM Laboratories Inc's supplier base and enhance supply chain resilience.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports, ensuring that all imported drugs meet standards for quality, safety, and effectiveness.

The FDA's importation policies are designed to protect public health by promoting supply chain integrity and ensuring that medicines imported into the U.S. comply with applicable legal and regulatory requirements. Imported drugs must meet FDA standards, and the agency reviews shipments to determine their admissibility into the U.S. market. Drugs that are adulterated, misbranded, or unapproved may be refused entry.

Import licensing requirements for pharmaceutical products entering the United States are stringent. All foreign drug establishments whose products are imported must register with the FDA and list all their drug products in commercial distribution in the U.S. This registration ensures that the FDA is notified of all regulated products imported into the United States.

Good Manufacturing Practice (GMP) certification is a critical component of the import process. The FDA recognizes GMP certifications from various international standards, including EU GMP, WHO GMP, and PIC/S. These certifications attest to the quality and safety of pharmaceutical products. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products, ensuring compliance with federal and state regulations.

Imported pharmaceutical products must adhere to FDA's labeling requirements, which include providing accurate and truthful information in English. The labeling must comply with FDA regulations to ensure that consumers and healthcare providers have the necessary information for safe and effective use.

Batch testing and stability requirements are essential to ensure the safety and efficacy of pharmaceutical products. Imported drugs are subject to FDA inspection and may be detained if they appear to violate FDA requirements. If a product is found to be violative, the FDA may issue a Notice of Detention and Hearing, specifying a place and time period for the importer to introduce testimony concerning the acceptability of the product.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products from India. These changes include enhanced scrutiny of manufacturing practices, stricter enforcement of labeling requirements, and increased inspections of foreign manufacturing facilities. The FDA has also updated its guidelines for the importation of certain prescription drugs, including biological products, to ensure they meet U.S. standards for safety and efficacy.

OHM Laboratories Inc's product category focus on antihistamines, respiratory and over-the-counter (OTC) medications, and medical devices and diagnostics aligns with prevalent health concerns in the United States. The high import values of products like Pseudoephedrine, Ephedrine, and Fexofenadine indicate a strategic emphasis on addressing respiratory issues and allergies, which are common among the U.S. population. The inclusion of medical devices and diagnostics in their portfolio suggests a comprehensive approach to healthcare, catering to both therapeutic and diagnostic needs.

The market demand for these products is driven by the widespread prevalence of allergic conditions, respiratory disorders, and the need for accessible diagnostic tools. By focusing on these therapeutic areas, OHM Laboratories Inc positions itself to meet significant healthcare needs, ensuring a steady demand for its imported products.

OHM Laboratories Inc's sourcing strategy is centered on importing generic drug formulations from India, leveraging the country's robust pharmaceutical manufacturing capabilities. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products, streamlining the supply chain and reducing time to market. India's established reputation for producing high-quality generic medications aligns with OHM Laboratories Inc's procurement objectives.

India's role as a global supplier of affordable therapeutics, including many life-saving medicines for chronic conditions, makes it a strategic partner for OHM Laboratories Inc. The country's pharmaceutical industry is recognized for its capacity to meet international standards, providing a reliable source for OHM Laboratories Inc's sourcing needs.

Based on its product mix, OHM Laboratories Inc serves the U.S. pharmaceutical market by importing generic medications and medical devices, positioning itself as a key player in the wholesale distribution segment. The company's focus on high-demand therapeutic areas such as antihistamines, respiratory medications, and medical devices enables it to cater to a broad spectrum of healthcare providers, including retail pharmacies, hospitals, and clinics. By